<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03399773</url>
  </required_header>
  <id_info>
    <org_study_id>9910</org_study_id>
    <secondary_id>NCI-2017-02205</secondary_id>
    <secondary_id>9910</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>P50HL110787</secondary_id>
    <secondary_id>RG9218003</secondary_id>
    <nct_id>NCT03399773</nct_id>
  </id_info>
  <brief_title>Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes</brief_title>
  <official_title>Pilot Study: Infusion of Off the Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (NLA101) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nohla Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well donor umbilical cord blood transplant with ex-vivo&#xD;
      expanded cord blood progenitor cells (NLA101) works in treating patients with blood cancer.&#xD;
      Before the transplant, patients will receive chemotherapy (fludarabine, cyclophosphamide and&#xD;
      in some cases thiotepa) and radiation therapy. Giving chemotherapy and total-body irradiation&#xD;
      before a donor umbilical cord blood transplant helps stop the growth of cells in the bone&#xD;
      marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop&#xD;
      the patient's immune system from rejecting the donor's stem cells. When the healthy stem&#xD;
      cells from a donor are infused into the patient they may help the patient's bone marrow make&#xD;
      stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may&#xD;
      also replace the patient's immune cells and help destroy any remaining cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      Patients receive either regimen A or regimen B.&#xD;
&#xD;
      REGIMEN A: Patients (18 through 45 years old) receive fludarabine intravenously (IV) over 30&#xD;
      minutes on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo total&#xD;
      body irradiation (TBI) twice daily (BID) on days -4 to -1. Patients receive unmanipulated&#xD;
      cord blood unit IV followed by NLA101 IV within the next 24 hours on day 0.&#xD;
&#xD;
      REGIMEN B: Patients (18 through 65 years old) receive fludarabine IV over 30-60 minutes on&#xD;
      days -6 to -3 and IV over 30 minutes on day -2, cyclophosphamide IV on day -6, and thiotepa&#xD;
      IV over 2-4 hours on days -5 and -4. Patients receive unmanipulated cord blood unit IV&#xD;
      followed by NLA101 IV within the next 24 hours on day 0.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 180 days, 1 year, and 2&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of graft failure</measure>
    <time_frame>Up to day 45 post-transplant</time_frame>
    <description>Primary graft failure/rejection as defined by no neutrophil recovery (regardless of donor chimerism) or autologous recovery (neutrophil recovery but &lt; 10% donor chimerism in blood and bone marrow [BM]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of acute graft versus host disease (GVHD)</measure>
    <time_frame>At day 100 post-transplant</time_frame>
    <description>Assessed using the Acute GVHD Grading Scale (reference: Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-8).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of chronic graft versus host disease (GVHD)</measure>
    <time_frame>Up to approximately 2 years post-transplant</time_frame>
    <description>Assessed using the Chronic GVHD Grading Scale (reference: Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group report. Blood Marrow Transplant 2005; 11: 945-56).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>Up to day 45 post-transplant</time_frame>
    <description>The day of neutrophil recovery will be the 1st day of 2 consecutive days of absolute neutrophil count at or above 500 after the 1st post-cord blood transplant nadir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet engraftment</measure>
    <time_frame>Up to day 100 post-transplant</time_frame>
    <description>Measured by the number of participants with a platelet count &gt; 20,000/ul without subsequent transfusions for 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to day 100 post-transplant</time_frame>
    <description>Toxicities will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-relapse mortality</measure>
    <time_frame>At day 100 post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-relapse mortality</measure>
    <time_frame>At 1 year post-transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Acute Biphenotypic Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myelodysplastic Syndrome With Excess Blasts</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive either regimen A or regimen B.&#xD;
REGIMEN A: Patients (18 through 45 years old) receive fludarabine IV over 30 minutes on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI BID on days -4 to -1. Patients receive unmanipulated cord blood unit IV followed by NLA101 IV within the next 24 hours on day 0.&#xD;
REGIMEN B: Patients (18 through 65 years old) receive fludarabine IV over 30-60 minutes on days -6 to -3 and IV over 30 minutes on day -2, cyclophosphamide IV on day -6, and thiotepa IV over 2-4 hours on days -5 and -4. Patients receive unmanipulated cord blood unit IV followed by NLA101 IV within the next 24 hours on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Omidubicel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
    <other_name>Ex Vivo-expanded Umbilical Cord Blood-derived Hematopoietic CD34-positive Progenitor Cells</other_name>
    <other_name>UCB-derived CD34+ HPCs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
    <other_name>Carloxan</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
    <other_name>fluoroadenine</other_name>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>Tepadina</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamine</other_name>
    <other_name>Thiofosfamide</other_name>
    <other_name>Thiofozil</other_name>
    <other_name>Thiophosphoramide</other_name>
    <other_name>Thiotef</other_name>
    <other_name>Triethylene Thiophosphoramide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
    <other_name>SCT_TBI</other_name>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Umbilical Cord Blood Transplantation</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
    <other_name>Cord Blood Transplantation</other_name>
    <other_name>UCB transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must have hematologic malignancy that meets institutional eligibility&#xD;
             requirements for cord blood transplant&#xD;
&#xD;
          -  Malignancies included are:&#xD;
&#xD;
               -  Acute leukemia, including Acute myeloid leukemia (AML), biphenotypic acute&#xD;
                  leukemia or mixed-lineage leukemia, acute lymphoblastic leukemia (ALL); all&#xD;
                  patients must be in complete response (CR) as defined by &lt; 5% blasts by&#xD;
                  morphology/flow cytometry in a representative bone marrow sample with adequate&#xD;
                  cellularity to assess remission status&#xD;
&#xD;
               -  Myelodysplasia (MDS) International Prognostic Scoring System (IPSS) intermediate&#xD;
                  (Int)-2 or high risk (i.e., RAEB, RAEBt) or refractory anemia with severe&#xD;
                  pancytopenia or high risk cytogenetics; blasts must be &lt; 10% in a representative&#xD;
                  bone marrow aspirate&#xD;
&#xD;
               -  Chronic Myeloid Leukemia excluding refractory blast crisis; to be eligible in&#xD;
                  first chronic phase (CP1) patient must have failed or be intolerant to tyrosine&#xD;
                  kinase inhibitor therapy&#xD;
&#xD;
          -  High dose TBI regimen: 18 to =&lt; 45 years&#xD;
&#xD;
          -  Intermediate intensity regimen: 18 =&lt; 65 years&#xD;
&#xD;
          -  Patients 18 to =&lt; 45 years: Karnofsky (&gt;= 18 years old) &gt;= 70 or Eastern Cooperative&#xD;
             Oncology Group (ECOG) 0-1&#xD;
&#xD;
          -  Patients &gt; 45 to =&lt; 65 years: Karnofsky &gt;= 70 or ECOG 0-1 and non-age adjusted&#xD;
             comorbidity index =&lt; 5&#xD;
&#xD;
          -  Calculated creatinine clearance must be &gt; 60 mL and serum creatinine =&lt; 2 mg/dL&#xD;
&#xD;
          -  Total serum bilirubin must be &lt; 3 mg/dL unless the elevation is thought to be due to&#xD;
             Gilbert's disease or hemolysis&#xD;
&#xD;
          -  Transaminases must be &lt; 3 x the upper limit of normal per reference values of treating&#xD;
             institution&#xD;
&#xD;
          -  Carbon monoxide diffusing capability (DLCO) corrected &gt;= 60% normal (may not be on&#xD;
             supplemental oxygen)&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt;= 50% OR&#xD;
&#xD;
          -  Shortening fraction &gt; 26%&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent form&#xD;
&#xD;
          -  DONOR: Minimum requirement: The cord blood (CB) unit must be matched at a minimum at&#xD;
             4/6 HLA-A, B antigens and DRB1 allele with the recipient; therefore, 0-2 mismatches at&#xD;
             the A or B or DRB1 loci based on intermediate resolution at HLA-A, B and high&#xD;
             resolution allele level typing at HLA- DRB1 are allowed&#xD;
&#xD;
          -  DONOR: Institutional guidelines for HLA-match may be followed as long as the minimum&#xD;
             criteria for HLA-matching as above are met&#xD;
&#xD;
          -  DONOR: The CB unit selected for transplant must have a MINIMUM of 2.5 x 10^7 TNC/kg&#xD;
&#xD;
          -  DONOR: The minimum recommended CD34/kg cell dose is 1.7 x 10^5 CD34/kg&#xD;
&#xD;
          -  DONOR: A domestic backup unit, meeting the same HLA and cell dose requirements, must&#xD;
             be identified and reserved prior to the start of the treatment plan for possible&#xD;
             infusion in the unlikely event of poor post-thaw viability of the primary CB unit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled viral or bacterial infection at the time of study enrollment&#xD;
&#xD;
          -  Active or recent (prior 6 month) invasive fungal infection unless cleared by&#xD;
             innovation and development (ID) consult&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Prior allogeneic transplant&#xD;
&#xD;
          -  Central nervous system (CNS) leukemic involvement not clearing with intrathecal&#xD;
             chemotherapy; diagnostic lumbar puncture is to be performed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filippo Milano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Filippo Milano</last_name>
    <phone>206.667.5925</phone>
    <email>fmilano@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Filippo Milano</last_name>
      <phone>206-667-5925</phone>
      <email>fmilano@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Filippo Milano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 15, 2017</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2018</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

